{"id":249888,"date":"2024-07-31T00:00:00","date_gmt":"2024-07-31T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcv0005-2024-biopharma-venous-thromboembolism-landscape-forecast\/"},"modified":"2026-03-31T10:29:00","modified_gmt":"2026-03-31T10:29:00","slug":"dlsfcv0005-2024-biopharma-venous-thromboembolism-landscape-forecast-disease-landscape-forecast","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcv0005-2024-biopharma-venous-thromboembolism-landscape-forecast-disease-landscape-forecast\/","title":{"rendered":"Venous Thromboembolism &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast"},"content":{"rendered":"<p>Venous thromboembolism (<abbr title=\"venous thromboembolism\">VTE<\/abbr>) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (<abbr title=\"deep vein thrombosis\">DVT<\/abbr>) and pulmonary embolism (<abbr title=\"pulmonary embolism\">PE<\/abbr>), depending on the location of the obstruction. Pharmacological treatment of patients diagnosed with <abbr title=\"venous thromboembolism\">VTE<\/abbr> consists mainly of anticoagulant therapy and, in some severe cases such as <abbr title=\"pulmonary embolism\">PE<\/abbr>, thrombolytics. Patients at high risk of <abbr title=\"venous thromboembolism\">VTE<\/abbr> receive primary prophylaxis with anticoagulants. These patients include hospitalized medically ill patients, patients undergoing orthopedic or non-orthopedic surgery, and cancer patients. In recent years, oral direct <abbr title=\"factor X activated\">FXa<\/abbr> inhibitors have become more widely used and have driven the growth of the <abbr title=\"venous thromboembolism\">VTE<\/abbr> market. Therapies in the <abbr title=\"venous thromboembolism\">VTE<\/abbr> pipeline include Anthos Therapeutics\u2019 abemaciclib and Bristol Myers Squibb \/ Johnson &#038; Johnson Innovative Medicine\u2019s milvexian. Both are factor XI\/XIa inhibitors and may prove safer than current therapies.<\/p>\n<p><strong>Questions answered <\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the key treatment drivers and goals within <abbr title=\"venous thromboembolism\">VTE<\/abbr>? How do current therapies perform on these goals?<\/li>\n<li>What do key opinion leaders think about Anthos Therapeutics\u2019 abemaciclib and Bristol Myers Squibb \/ Johnson &#038; Johnson Innovative Medicine\u2019s milvexian?<\/li>\n<li>How will genericization affect the market?<\/li>\n<li>What are the key unmet needs in the treatment of <abbr title=\"venous thromboembolism\">VTE<\/abbr>, and how likely are they to be met?<\/li>\n<\/ul>\n<p><strong>Geography:\u00a0<\/strong>United States, EU5, Japan<\/p>\n<p><strong>Primary research:\u00a0<\/strong>19 country-specific interviews with thought-leading hematologists, internists, cardiologists, orthopedic surgeons, vascular surgeons, and oncologists; supported by survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology:\u00a0<\/strong>Diagnosed and drug-treated VTE patients and patients eligible for VTE prophylaxis by country<\/p>\n<p><strong>Forecast:\u00a0<\/strong>10-year, annualized,\u00a0drug-level sales and patient share of key VTE therapies through 2033, segmented by brands \/ generics<\/p>\n<p><strong>Drug treatments:\u00a0<\/strong>Coverage of key current and emerging therapies<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution enhancements<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-249888","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-venous-thromboembolism","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249888\/revisions"}],"predecessor-version":[{"id":575929,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249888\/revisions\/575929"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}